XTRA:M12

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. More Details


Snowflake Analysis

High growth potential and good value.

Share Price & News

How has M1 Kliniken's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: M12 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.4%

M12

-5.1%

DE Healthcare

-1.3%

DE Market


1 Year Return

-28.9%

M12

-4.1%

DE Healthcare

2.9%

DE Market

Return vs Industry: M12 underperformed the German Healthcare industry which returned -2.1% over the past year.

Return vs Market: M12 underperformed the German Market which returned 3.9% over the past year.


Shareholder returns

M12IndustryMarket
7 Day0.4%-5.1%-1.3%
30 Day3.4%-5.0%-0.7%
90 Day-9.9%-14.0%-0.8%
1 Year-28.9%-28.9%-2.5%-4.1%6.2%2.9%
3 Year-13.6%-17.2%-30.4%-33.6%2.9%-6.0%
5 Year96.6%75.0%-25.9%-30.7%24.0%6.3%

Price Volatility Vs. Market

How volatile is M1 Kliniken's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is M1 Kliniken undervalued compared to its fair value and its price relative to the market?

45.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: M12 (€9.24) is trading below our estimate of fair value (€16.94)

Significantly Below Fair Value: M12 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: M12 is poor value based on its PE Ratio (20.6x) compared to the DE Healthcare industry average (18.3x).

PE vs Market: M12 is good value based on its PE Ratio (20.6x) compared to the German market (22.7x).


Price to Earnings Growth Ratio

PEG Ratio: M12 is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: M12 is overvalued based on its PB Ratio (2.5x) compared to the DE Healthcare industry average (1.1x).


Next Steps

Future Growth

How is M1 Kliniken forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

35.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: M12's forecast earnings growth (35% per year) is above the savings rate (0.2%).

Earnings vs Market: M12's earnings (35% per year) are forecast to grow faster than the German market (26.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: M12's revenue (22.2% per year) is forecast to grow faster than the German market (6.1% per year).

High Growth Revenue: M12's revenue (22.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: M12's Return on Equity is forecast to be low in 3 years time (8.8%).


Next Steps

Past Performance

How has M1 Kliniken performed over the past 5 years?

3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: M12 has a high level of non-cash earnings.

Growing Profit Margin: M12's current net profit margins (10.6%) are higher than last year (10.5%).


Past Earnings Growth Analysis

Earnings Trend: M12's earnings have grown by 3.9% per year over the past 5 years.

Accelerating Growth: M12's earnings growth over the past year (7%) exceeds its 5-year average (3.9% per year).

Earnings vs Industry: M12 earnings growth over the past year (7%) exceeded the Healthcare industry 6%.


Return on Equity

High ROE: M12's Return on Equity (10.7%) is considered low.


Next Steps

Financial Health

How is M1 Kliniken's financial position?


Financial Position Analysis

Short Term Liabilities: M12's short term assets (€61.7M) exceed its short term liabilities (€5.6M).

Long Term Liabilities: M12's short term assets (€61.7M) exceed its long term liabilities (€14.1M).


Debt to Equity History and Analysis

Debt Level: M12's debt to equity ratio (7%) is considered satisfactory.

Reducing Debt: M12's debt to equity ratio has increased from 3.7% to 7% over the past 5 years.

Debt Coverage: M12's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: M12 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is M1 Kliniken current dividend yield, its reliability and sustainability?

3.25%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: M12's dividend (3.25%) is higher than the bottom 25% of dividend payers in the German market (1.18%).

High Dividend: M12's dividend (3.25%) is low compared to the top 25% of dividend payers in the German market (3.71%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, M12 has been paying a dividend for less than 10 years.

Growing Dividend: M12 has only been paying a dividend for 4 years, and since then payments have not increased.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (66.8%), M12's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: M12's dividends in 3 years are forecast to be thoroughly covered by earnings (13.4% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure


CEO

Patrick Brenske

no data

Tenure

Mr. Patrick Brenske has been Chief Executive Officer of MPH Health Care AG (formerly known as MPH Mittelständische Pharma Holding AG) since January 23, 2009 and has been its Member of Management Board sinc ...


Board Members

NamePositionTenureCompensationOwnership
Albert Wahl
Chairman of Supervisory Board3.33yrsno datano data
Sabine Meck
Member of Supervisory Board5.33yrsno datano data
Uwe Zimdars
Deputy Chairman of Supervisory Board3.33yrsno datano data

3.3yrs

Average Tenure

Experienced Board: M12's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.


Top Shareholders

Company Information

M1 Kliniken AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: M1 Kliniken AG
  • Ticker: M12
  • Exchange: XTRA
  • Founded: 2007
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: €181.505m
  • Shares outstanding: 19.64m
  • Website: https://www.m1-kliniken.de

Number of Employees


Location

  • M1 Kliniken AG
  • GrUenauer Strasse 5
  • Berlin
  • Berlin
  • 12557
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
M12DB (Deutsche Boerse AG)YesBearer SharesDEEURSep 2015
M12XTRA (XETRA Trading Platform)YesBearer SharesDEEURSep 2015

Biography

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. The company operates through Beauty and Trade segments. It develops and markets pharmac ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/19 22:03
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.